Insulin Regulation of Lipolysis and Lipolysis Proteins

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2025

Conditions
Obesity
Interventions
BEHAVIORAL

Immediate weight loss

Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

DRUG

Pioglitazone

Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

BEHAVIORAL

Deferred weight loss

Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

DRUG

Placebo

Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT03866408 - Insulin Regulation of Lipolysis and Lipolysis Proteins | Biotech Hunter | Biotech Hunter